Health
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
PRINCETON, N.J., March 07, 2026--U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/5ba823c24d759bdffd4bd82e46e061bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NxvVrNjnryaKCuZdEguLyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5ba823c24d759bdffd4bd82e46e061bd","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Tvxj7kxAE2MguBjY52XypQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5ba823c24d759bdffd4bd82e46e061bd","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"Sotyktu is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved for this indication","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., March 07, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu® (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).1 Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA.","length":370,"tagName":"p"},{"type":"text","content":""Today’s announcement marks the introduction of a new, differentiated option to treat adults with active psoriatic arthritis," said Al Reba, senior vice president, Cardiovascular & Immunology Commercialization, Bristol Myers Squibb. "This latest approval of Sotyktu confirms its important role in managing both skin and joint symptoms of psoriatic disease and is a key milestone as we continue to explore its development in diseases that have limited or no treatment options."","length":500,"tagName":"p"},{"type":"text","content":"This FDA approval is based on positive results from the pivotal POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of Sotyktu 6 mg once daily in adults with active psoriatic arthritis. In...